Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes.

Breast · 2024 · PMC10791571 · PMID 38176305

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

did not reach statistical significancep = 0.1so close (0.05 < p ≤ 0.1)

found that dose-dense treatment was associated with greater risk of acute leukemia or myelodysplastic syndromes (MDS), however, the pooled relative risks did not reach statistical significance (p = 0.1) [ 44 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.